Enlicitide, an oral cholesterol-lowering drug, is drawing interest from clinicians as an option for patients who would rather skip injections. Merck has also reached a milestone in its cholesterol drug pipeline, while a cholesterol medicine backed by McMaster University science has received approval in Canada.

Health outlets this week looked into how exercise influences LDL cholesterol, and TODAY.com urged readers to be careful about following cholesterol advice found on social media. LDL cholesterol is widely known as the 'bad' type because raised levels increase the risk of heart disease.